147 related articles for article (PubMed ID: 21527292)
1. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7.
Pasche N; Woytschak J; Wulhfard S; Villa A; Frey K; Neri D
J Biotechnol; 2011 Jun; 154(1):84-92. PubMed ID: 21527292
[TBL] [Abstract][Full Text] [Related]
2. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
3. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
Frey K; Zivanovic A; Schwager K; Neri D
Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
5. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.
Sommavilla R; Pasche N; Trachsel E; Giovannoni L; Roesli C; Villa A; Neri D; Kaspar M
Protein Eng Des Sel; 2010 Aug; 23(8):653-61. PubMed ID: 20551083
[TBL] [Abstract][Full Text] [Related]
6. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
7. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
8. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.
Schwager K; Bootz F; Imesch P; Kaspar M; Trachsel E; Neri D
Hum Reprod; 2011 Sep; 26(9):2344-52. PubMed ID: 21705369
[TBL] [Abstract][Full Text] [Related]
9. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
Kaspar M; Trachsel E; Neri D
Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
11. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
12. The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate.
Pasche N; Frey K; Neri D
Angiogenesis; 2012 Mar; 15(1):165-9. PubMed ID: 22052195
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications.
Steiner M; Gutbrodt K; Krall N; Neri D
Bioconjug Chem; 2013 Feb; 24(2):234-41. PubMed ID: 23350721
[TBL] [Abstract][Full Text] [Related]
15. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
Winter J; Barbin K; Bacci C; Bunte T
J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
[TBL] [Abstract][Full Text] [Related]
16. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.
Hemmerle T; Neri D
Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141
[TBL] [Abstract][Full Text] [Related]
17. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.
Doll F; Schwager K; Hemmerle T; Neri D
Arthritis Res Ther; 2013 Sep; 15(5):R138. PubMed ID: 24289726
[TBL] [Abstract][Full Text] [Related]
18. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
19. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
Frey K; Schliemann C; Schwager K; Giavazzi R; Johannsen M; Neri D
J Urol; 2010 Dec; 184(6):2540-8. PubMed ID: 21030045
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
De Luca R; Neri D
Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]